Interleukin-6 Receptor Antagonist [EPC]

72249 reported adverse events

Drugs of this class: SARILUMAB TOCILIZUMAB

These side effects are most commonly reported by patients taking drugs of the Interleukin-6 Receptor Antagonist [EPC] class:

# Side effect Count
0 DRUG INEFFECTIVE 25457
1 RHEUMATOID ARTHRITIS 14648
2 PAIN 11436
3 ARTHRALGIA 9095
4 OFF LABEL USE 8687
5 JOINT SWELLING 8299
6 FATIGUE 7491
7 DRUG INTOLERANCE 7339
8 RASH 6778
9 CONTRAINDICATED PRODUCT ADMINISTERED 6542
See all common reactions for Interleukin-6 Receptor Antagonist [EPC]

Drugs of the Interleukin-6 Receptor Antagonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 HUMAN ANTICHIMERIC ANTIBODY POSITIVE 269 0.9308
1 DISABILITY ASSESSMENT SCALE SCORE INCREASED 172 0.8687
2 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE 1537 0.8635
3 SWOLLEN JOINT COUNT INCREASED 262 0.8137
4 RED BLOOD CELL SEDIMENTATION RATE 133 0.8012
5 RHEUMATOID FACTOR NEGATIVE 123 0.7785
6 RHEUMATOID FACTOR POSITIVE 1626 0.7577
7 PEMPHIGUS 3348 0.7161
8 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY 39 0.6500
9 GRANULOMA SKIN 343 0.6282
See all enriched reactions for Interleukin-6 Receptor Antagonist [EPC]